Lascco
Company Team Projects Media Contact
         
 
 
NEWS

 

LASCCO Announces Positive Scientific Advice Meeting with MHRA and Plans a First-In-Man Clinical Trial with CAL02 in Patients with Severe Pneumococcal Pneumonia

October 22, 2014

GENEVA, SWITZERLAND – LASCCO SA has held a positive Scientific Advice Meeting with the UK MHRA regarding its broad-spectrum drug against bacterial virulence factors, CAL02. The company plans to conduct a first-in-human clinical study next year with CAL02 in severely-ill patients with pneumococcal pneumonia.

“We are very pleased to receive positive advice from MHRA’s experts on our preclinical and clinical program”, says Frédéric Lajaunias, co-founder and Managing Director of LASCCO. “We will promptly complete the non-clinical program needed to transition to the clinical stage with a view to initiating a first-in-man study, using CAL02 as an adjunctive treatment to standard of care for the treatment of severe pneumococcal pneumonia.”

Severe pneumococcal pneumonia accounts for 20% to 30% of intensive-care units’ patients, with a mortality rate that can exceed 30% despite best currently available therapy. Pre-clinical studies have shown that CAL02 has the potential to combat infections caused by the most frequent bacteria types regardless of their antibiotic resistance profile.

About CAL02

CAL02 is a broad-spectrum anti-virulence therapeutic agent targeting bacterial toxins for the treatment of severe infections, including those caused by antibiotic-resistant strains. It consists of two lipidic nanoparticles exclusively composed of ubiquitous dietary lipids constituents of the mammalian membranes. CAL02 acts in synergy with the antibiotics and also indirectly affects bacterial survival by depriving bacteria from the tools they use to feed and multiply, and by protecting the immune system, which can then appropriately combat the infection. The product is at preclinical stage.

About LASCCO SA

LASCCO SA is a Swiss-based biotechnology company dedicated to the development of discovery-stage biomedical technologies. For more information, please visit http://www.lascco.com.

Contact:

LASCCO SA - Rue de la Rôtisserie 8 - 1211 Geneva 3 – Switzerland

Phone: +41 (0)22 317 8881

Email: info@lascco.com

 

 
 


 
Lascco